

Myrna Candelaria

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5018785/myrna-candelaria-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11
papers

174
citations

7
h-index

12
g-index

12
ext. papers

211
ext. citations

3.1
avg, IF

2.44
L-index

#	Paper	IF	Citations
11	Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. <i>JCO Global Oncology</i> , 2021 , 7, 1151-1166	3.7	3
10	Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021 , 12, 2040620721989579 ³	5.7	3
9	A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 637-646	2	2
8	Rituximab biosimilar RTX83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3375-3385	1.9	11
7	CLINICAL CHARACTERISTICS OF PRIMARY EXTRANODAL VERSUS NODAL DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE COHORT STUDY IN A CANCER CENTER. <i>Revista De Investigacion Clinica</i> , 2019 , 71, 349-358	1.6	2
6	Comparative assessment of pharmacokinetics, and pharmacodynamics between RTX83 as rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 515-527	3.5	25
5	Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 481-487	5.9	22
4	Encouraging results with the compassionate use of hydralazine/valproate (TRANSCRIP) as epigenetic treatment for myelodysplastic syndrome (MDS). <i>Annals of Hematology</i> , 2017 , 96, 1825-1832 ³	3	11
3	Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico. <i>BioMed Research International</i> , 2016 , 2016, 9817606	3	8
2	DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. <i>PLoS ONE</i> , 2012 , 7, e29181	3.7	35
1	Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. <i>Annals of Hematology</i> , 2011 , 90, 379-87	3	52